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Abstract
Background: Assessing benefits and harms of health interventions is resource-intensive and often requires feasibility
and pilot trials followed by adequately powered randomised clinical trials. Data from feasibility and pilot trials are used
to inform the design and sample size of the adequately powered randomised clinical trials. When a randomised clinical
trial is conducted, results from feasibility and pilot trials may be disregarded in terms of benefits and harms.
Methods: We describe using feasibility and pilot trial data in the Trial Sequential Analysis software to estimate the
required sample size for one or more trials investigating a behavioural smoking cessation intervention. We show how
data from a new, planned trial can be combined with data from the earlier trials using trial sequential analysis methods
to assess the intervention’s effects.
Results: We provide a worked example to illustrate how we successfully used the Trial Sequential Analysis software to
arrive at a sensible sample size for a new randomised clinical trial and use it in the argumentation for research funds
for the trial.
Conclusions: Trial Sequential Analysis can utilise data from feasibility and pilot trials as well as other trials, to estimate a
sample size for one or more, similarly designed, future randomised clinical trials. As this method uses available data,
estimated sample sizes may be smaller than they would have been using conventional sample size estimation
methods.
Keywords: Meta-analysis, Trial sequential analysis methods, Trial Sequential Analysis software, Sample size, Information
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Background
Demonstrating that health interventions work requires sub-
stantial resources. Often feasibility and pilot randomised
clinical trials (RCTs) are conducted before larger-scale ran-
domised clinical trials are designed to determine benefits
and harms [1–3]. Feasibility trials are used to ascertain in-
formation such as intervention acceptability, feasibility of
intervention delivery, and recruitment likelihood to help
design more decisive RCTs [1]. A pilot trial is a smaller ver-
sion of a large-scale RCT, and is used to test whether the
main components of the trial, such as recruitment, ran-
domisation, treatment, and follow-up assessments can all
work together [1]. Moreover, their data can be used to in-
form sample sizes for large-scale RCTs [2, 3].
Trial sequential analysis is a methodology that can be
used in systematic reviews and meta-analyses to control
random errors, and to assess whether further trials need
to be conducted [4, 5]. Trial sequential analysis as a
method can be performed using the Trial Sequential
Analysis software, which is freely available alongside its
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user manual online at The Copenhagen Trial Unit web-
site [6]. Here we employ Trial Sequential Analysis and
combine data from feasibility and pilot RCTs testing a
text message-based smoking cessation intervention for
pregnant women (‘MiQuit’) [7, 8] to estimate the sample
size that one or more future RCTs would need to re-
cruit, to provide a more decisive answer regarding the
effect of the intervention. We also show how data from
the new, planned trial or trials can be combined with
data from earlier trials using Trial Sequential Analysis to
assess the intervention’s benefits and harms. Using Trial
Sequential Analysis sample size estimation methods
maximises use of available trial data and consequently,
the new RCT or trials may become smaller than they
would have been using conventional sample size estima-
tion methods.
Conventional meta-analysis
Meta-analyses often influence future research; when
planning future trials, investigators frequently use
meta-analysis to provide an accurate summary of an
intervention’s likely effect. If all available RCTs are
included, systematic reviews with meta-analyses are
considered the best available evidence, because power
and precision of the estimated intervention effect is
the best one can get [9, 10]. However, this does not
necessarily mean that the available evidence is either
sufficient or strong. Conventional meta-analysis
methods do not consider the amount of the available
evidence in relation to the required sample size [11–
13]. The reliability of a statistically significant inter-
vention effect generated by meta-analysis is often
overvalued, particularly where sparse data (number of
events and participants) or repetitive analyses (type I
errors) are employed [6, 10, 14, 15]. In other situa-
tions, intervention effects that are not statistically sig-
nificant are often interpreted as showing that the
intervention has no effect, and it is assumed that no
more evidence is required (type II errors) [16, 17].
In conventional meta-analysis, there is no way to
differentiate between an underpowered meta-analysis
and a true finding of an intervention being ‘ineffect-
ive’. However, it is imperative that a conclusion as to
whether an intervention is truly ineffective or truly ef-
fective is made as soon as possible after trials are
completed, in order to guide investigators’ decisions
as to whether further trials could be informative or
not [6]. Trial sequential analysis is a methodology
that can overcome this issue by distinguishing
whether meta-analyses provide evidence for either
beneficial or harmful intervention effects, lack of ef-
fect (futility), or insufficient evidence for evaluation of
the intervention effect [6, 18].
Methods
Trial sequential analysis
Meta-analyses aim to discover the benefit or harm of an
intervention as early and as reliably as possible. As a re-
sult, they tend to be updated when new trials are pub-
lished [19]. When intervention evaluation has just begun
and only few, smaller trials are available, meta-analyses
may be conducted on sparse amounts of data and are at
high risk of random type I and type II errors [20]. As
meta-analyses are updated they are subjected to repeated
significance testing, which increases the risk of type I er-
rors [21]. When there are few data available, the Trial
Sequential Analysis software resolves these issues by
having stringent thresholds for assessing statistical sig-
nificance, using monitoring boundaries. Monitoring
boundaries also take into account the volume of signifi-
cance testing which has been undertaken through
adjusting the thresholds that are used to define whether
or not results are considered statistically significant [6].
Trial Sequential Analysis is also able to assess when an
intervention has an effect smaller than what would be
considered clinically minimally important [6]. Futility
boundaries, originally developed for interim analysis in
RCTs, can be estimated and used to provide a threshold
below which an intervention would be considered to
have no clinically important effect [6]. Thus, performing
further trials is considered futile as the intervention does
not possess the postulated clinically minimally important
effect [6].
In Trial Sequential Analysis, when neither the moni-
toring boundaries nor the futility boundaries are crossed,
further information is usually required. Trial Sequential
Analysis can also inform how much more information is
required to get a conclusive answer regarding the effect
of the intervention versus its comparator – this is called
the distance between the accrued information and the
required information.
Required information size
For RCTs, an estimation of the required sample size is
performed to ensure the number of participants in-
cluded is enough to detect or reject a minimum clinic-
ally important effect size [17]. For binary outcomes, such
as death, the sample size estimation is based on the ex-
pected proportion of deaths in the control group, the ex-
pected relative risk reduction of the intervention, and
the selected maximum risks of both type I and type II
errors [18]. Similarly, for meta-analyses to produce ad-
equately powered findings regarding intervention effi-
cacy, sufficient numbers of participants need to be
included. This number is referred to as the ‘required in-
formation size’ (or ‘optimal information size’ or ‘meta-
analytic sample size’) [22, 23]. The meta-analytic re-
quired information size can be estimated using similar
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parameters as those used in sample size estimation
for a single trial if one uses a fixed-effect model. If
one intends to use a random-effects model, then one
needs to consider adjusting for any between-study
heterogeneity measured by inconsistency (I2) or diver-
sity (D2) [18]. Inconsistency is the test statistic for
heterogeneity usually used in meta-analysis, and diver-
sity characterises the proportion of between trial vari-
ation in any meta-analysis relative to the total model
variance of the included trials [24]. Diversity is equal
to inconsistency or larger [24]. Heterogeneity between
studies is likely to be observed in meta-analyses due
to the magnitude of the intervention effect varying
when used in different study populations, in studies
with different methodological characteristics, or due
to variations in the intervention itself [13]. Thus,
sample size estimations need to be increased to allow
for this between-trial heterogeneity [18].
In the Trial Sequential Analysis software, trials are
chronologically ordered, and interim analyses are con-
ducted as each trial is added using summary data from
each trial. In a trial sequential analysis where the ‘re-
quired information size’ has not been reached, the
threshold for statistical significance is inflated to account
for sparse data and multiple testing of the interim ana-
lyses using monitoring boundaries; thus, the 95% confi-
dence interval is not providing coverage of the real
uncertainty and the cut-off for determining statistical
significance is below the usual nominal figure of 0.05
[18]. Furthermore, the Trial Sequential Analysis software
provides adjusted confidence intervals if the ‘required in-
formation size’ has not been reached, which we refer to
as Trial Sequential Analysis-adjusted confidence inter-
vals [18]. Technical details regarding how monitoring
boundaries, information size, and Trial Sequential
Analysis-adjusted confidence intervals are calculated can
be found elsewhere [6, 18]. Other statistical software,
such as STATA and packages in R, could potentially be
programmed to perform trial sequential analysis how-
ever to our knowledge these have only been performed
on hazard ratios for time-to-event data [25, 26].
In the worked examples below, we show how the Trial
Sequential Analysis software can be used to estimate the
sample size required for one or more new trials to add
further data to a meta-analysis to provide more firm evi-
dence for an intervention either having or not having
the postulated effect.
Results
In this section, we provide an example of how Trial Se-
quential Analysis successfully used data from feasibility
and pilot RCTs that tested MiQuit, a text-message, self-
help smoking cessation intervention for pregnant
women, to justify research funds to undertake a third,
more adequately powered RCT.
Previous MiQuit trials
Smoking during pregnancy increases the risk of miscar-
riage, stillbirth, low birth-weight, premature birth, peri-
natal morbidity and mortality, sudden infant death, as
well as adverse infant behavioural outcomes [27, 28].
Pregnancy is a life event which motivates cessation at-
tempts amongst smokers and over 50% of pregnant
women who smoke attempt to quit during this time
[29], consequently pregnancy is an opportune moment
to offer smoking cessation support. Text message, self-
help support, smoking cessation programmes developed
for non-pregnant smokers are effective, but such pro-
grammes are inappropriate for use during pregnancy
[30–32]. To address the lack of acceptable self-help, sup-
port cessation programmes for pregnant smokers in the
UK, MiQuit was developed [7]. MiQuit delivers
individually-tailored text messages to pregnant smokers,
with the aim of encouraging them to stop smoking [7].
Further details on MiQuit can be found elsewhere [7].
A MiQuit feasibility RCT was conducted, including
207 women. Biochemically-validated, 7-day point preva-
lence cessation at 12 weeks post randomisation (~ 6
months gestation) was 12.5% in the experimental
MiQuit group, compared with 7.8% in the control group
(odds ratio (OR) 1.68, 95% confidence interval (CI) 0.66
to 4.31) [7]. Although the trial was small, and the cessa-
tion period brief, the trial provided an estimate suggest-
ing that MiQuit could have a positive impact in addition
to routine care.
The feasibility RCT lead to minor changes to the inter-
vention, before a pilot RCT was conducted to investigate
the feasibility of undertaking a fully-powered multi-
centre RCT in UK National Health Service (NHS) set-
tings [8]. The pilot MiQuit RCT recruited 407 pregnant
women that smoke, which had largely similar baseline
characteristics to those in the feasibility RCT. The self-
reported abstinence from 4 weeks post-randomisation
until late pregnancy follow-up (approximately 36 weeks
gestation) biochemically validated at follow-up was 5.4%
in the experimental MiQuit group versus 2.0% in the
control group (OR 2.70, 95% CI 0.93 to 9.35) [8]. This
trial also suggested a beneficial effect of MiQuit.
As MiQuit is a cheap intervention and can be dissemi-
nated widely, it was anticipated that even a 1 to 2% abso-
lute effect on smoking cessation in pregnancy could be
clinically important and cost effective [8]. The results
from the feasibility and pilot trials suggested that an im-
pact of this size was attainable; however, an adequately
powered RCT would still be needed to determine
whether MiQuit is effective and guide future routine
clinical practise.
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Conventional meta-analysis
The conventional way to determine if an intervention
is effective or not is to use the naïve alpha of 5% and
the naïve 95% confidence interval [10]. Since both the
feasibility and pilot trials used almost the same design
as was planned to be used in the new RCT, they can
be considered as pilots and it would be appropriate
to meta-analyse these trials’ findings together. Using a
random-effects model, a traditional meta-analysis of
pilot and feasibility studies’ data found, that women
randomised to MiQuit were more than twice as likely
to be abstinent in their pregnancy (pooled OR 2.26,
95% CI 1.04 to 4.93; I2 = 0%, p = 0.041). This result
seems to be significant according to conventional as-
sessment (p < 0.05). However, this result should be
interpreted with caution because, as described above,
findings from meta-analyses based on only two small
RCTs can produce spurious findings due to type I
error [11, 12, 22] (please see below).
In the next sections, we use conventional sample size
estimation methods to estimate the sample size for an
RCT which, on its own would have enough power to
show whether MiQuit might be effective, using a plaus-
ible treatment effect estimate derived from the conven-
tional meta-analysis above. We also calculate a second
sample size estimate for one or more further RCTs,
which when pooled with data from feasibility and pilot
trials using Trial Sequential Analysis methods, would be
similarly decisive.
Conventional sample size estimation
As the pilot trial [8] was considered at lower risk of bias
compared to the feasibility trial [7], a traditional sample
size calculation using smoking cessation rate estimates
derived from the pilot trial suggests a new trial would
require a total sample size of 1292 participants. This es-
timate has 90% power (10% type II error) and 5% signifi-
cance (2-sided test; type I error) to detect a 3.4%
absolute difference in prolonged abstinence from smok-
ing from 4 weeks after enrolment until 36 weeks gesta-
tion between the MiQuit and control groups (5.4%
versus 2.0%) [8].
Trial sequential analysis
Figure 1 I illustrates a Trial Sequential Analysis incorp-
orating findings from the MiQuit feasibility (A) [7] and
pilot (B) [8] trials. In this Trial Sequential Analysis out-
put, the x-axis represents the number of participants
and marked on this are the numbers of participants re-
cruited to each trial. The y-axis represents the z-score,
where a positive z-score favours the MiQuit intervention
and a negative z-score favours the control
The z-score is the test that helps you decide whether
to accept or reject the null hypothesis. Very high positive
or very low negative z-scores are associated with very
small p-values. The critical z-score values when using a
95% confidence level, which are known as the ‘conven-
tional test boundaries’, are − 1.96 and + 1.96 and these
relate to a two-sided p-value of 0.05. If the z-score is be-
tween − 1.96 and + 1.96, the p-value will be larger than
0.05, and the null hypothesis of no difference between
intervention groups is accepted. The z-curve represents
the cumulative z-score as each RCT is added to the
analysis. In Fig. 1.I, when trial B is added to the ana-
lysis, the z-curve crosses the conventional test bound-
ary (p = 0.05). This is consistent with the results from
the conventional meta-analysis for MiQuit, where we
found p = 0.041.
The required information size is represented by the
vertical red line in Fig. 1. The required information size
was estimated using the same variables as used for the
conventional sample size estimation above (90% power,
5% significance, to detect a 3.4% absolute difference) [8];
although this estimate could take into account observed
heterogeneity, there was none in this meta-analysis (I2 =
0% and D2 = 0). Consequently, the estimated required in-
formation size of 1296 participants is only slightly differ-
ent to that using conventional sample size estimation
due to rounding errors. The estimate would be larger if
heterogeneity were present.
As the cumulative z-curve does not cross the upper
trial sequential monitoring boundary for benefit, this
Trial Sequential Analysis shows that further information
is required before any firm conclusion can be reached
about MiQuit efficacy. Although the conventional meta-
analysis suggested, with borderline significance, that
pregnant women randomised to MiQuit were more than
twice as likely to be abstinent from smoking in late preg-
nancy, the Trial Sequential Analysis software shows that
this finding is not sufficiently robust. The Trial Sequen-
tial Analysis-adjusted confidence intervals for cessation
using MiQuit (pooled OR 2.26, Trial Sequential
Analysis-adjusted CI 0.66 to 7.70), are much wider than
those of the conventional meta-analysis (pooled OR
2.26, 95% CI 1.04 to 4.93).
Without Trial Sequential Analysis having been under-
taken, an interpretation of the conventional meta-
analysis would have been that MiQuit is effective. How-
ever, Trial Sequential Analysis indicates that one cannot
be secure in this interpretation and further trial data
should be collected to eliminate the possibility that this
is a false positive result, which can occur early in inter-
vention evaluation when small trials are undertaken.
Calculating sample size for a third MiQuit RCT
Trial Sequential Analysis has demonstrated that further
RCT data are required before a firm conclusion about
MiQuit efficacy can be determined. As the initial two
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trials were sufficiently similar to be combined in Trial
Sequential Analysis, we will now demonstrate how Trial
Sequential Analysis can be used to estimate the sample
size for (a) further trial(s) – data from which, when com-
bined with the previous two trials in the Trial Sequential
Analysis software, would be expected to provide a more
decisive answer regarding MiQuit efficacy. We will also
demonstrate how exemplar theoretical findings from fu-
ture trials which are both in favour and against MiQuit
having a positive effect would impact the Trial Sequen-
tial Analysis result.
Trial sequential analysis sample size estimation
Estimates derived from the Trial Sequential Analysis
found the required information size as 1296 participants.
From the feasibility and pilot studies, 605 women have
already been recruited and randomised; therefore, the
required sample size for further RCTs can be estimated
as the difference between the required information size
minus the number of women already recruited into the
previous trials; thus a sample size of 691 women (346
per intervention group) would be needed, assuming a 1:
1 ratio.
Figure 1 II shows the Trial Sequential Analysis output
after adding a theoretical third trial (C) with a sample
size of 630 women (315 per trial group), where an abso-
lute difference of 3.17% was observed in favour of the
MiQuit group versus the control group. The Trial Se-
quential Analysis clearly shows the cumulative z-curve
line crossing the upper trial sequential monitoring
boundary which indicates MiQuit being effective. As the
trial sequential monitoring boundary has been crossed,
the Trial Sequential Analysis z-curve does not need to
reach the required information size of 1296. In the
present scenario, we can firmly conclude that MiQuit is
effective for smoking cessation compared with control
(provided that all trials are valid and not influenced by
systematic errors (bias) or other errors)
When a theoretical third trial (D) with a negative out-
come is included in the Trial Sequential Analysis (Fig.
1.III), we observe a different output. Here, the third trial
of sample size 630 was intentionally given a negative
outcome (absolute difference of − 0.63% in favour of
control). Here we observe the z-curve drop below the
conventional test boundary, and in a meta-analysis we
would have concluded that MiQuit was not effective.
However, in the Trial Sequential Analysis, the futility
boundary is not crossed, so we are unable to decisively
say that MiQuit is not as effective as control for smoking
cessation. Due to the diversity, the required information
size has increased to 1941, meaning future trials will
need a further 706 participants.
A conservative approach to sample size estimation using
trial sequential analysis
In the above example, the required information size was
derived using the smoking cessation effect from the pilot
trial [8]. Therefore, it can be contested whether data
from the pilot trial should be included in subsequent
Trial Sequential Analysis. Consequently, one could ex-
clude the data from the pilot trial from the Trial Se-
quential Analysis and re-estimate the total number
required (Fig. 2. I). Using this approach, to provide a
conclusive result, either a single trial of 1098 participants
(549 per intervention group, assuming a 1:1 ratio) or
multiple trials cumulating to a total of 1098 participants,
would be needed. This figure, although conservative, is
still less than the estimate from the conventional sample
size calculation.
Figure 2 II and 2.III also show the Trial Sequential Ana-
lysis outputs if theoretical trials C and D were included in
the analyses. In both situations further information is
needed, despite the z-curve coming close to the upper trial
sequential monitoring boundary in Fig. 2.II and the futility
boundary in Fig. 2. III
Sensitivity analysis
The modelled scenario, in which there is no heterogen-
eity between trials in a meta-analysis is rare; in most sit-
uations where the described approach is used, some
heterogeneity between studies is to be expected. Trial
Sequential Analysis provides 95% confidence intervals
for heterogeneity (D2) within meta-analyses. One way to
fully allow for heterogeneity is to perform a sensitivity
analysis using the upper 95% confidence interval for the
between-trial heterogeneity variance estimate. This
would increase the required information size. In our ex-
ample, the program could not calculate the 95% confi-
dence interval surrounding the D2 of 0% as there were
less than three included studies. In this case it is possible
to input an estimate for heterogeneity into the Trial Se-
quential Analysis software.
(See figure on previous page.)
Fig. 1 I. Trial Sequential Analysis output of both MiQuit trials using 90% power, 5% significance, to detect a 3.4% absolute difference. Diversity =
0%. Points A and B on the z-curve represent each trial added to the sequential analysis. A – Feasibility trial [7], B – Pilot trial [8]. Monitoring
boundaries in Fig. 1 use the Lan-DeMets O’Brien-Fleming alpha-spending approach. II. Point C represents a theoretical trial with a sample size of
630 women, where an absolute difference of 3.17% was observed, in favour of the MiQuit group versus the control group. Diversity = 0%. III.
Point D represents a theoretical trial with a sample size of 630 women, with an absolute difference of − 0.63% in favour of the control
group. Diversity = 33%
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Discussion
The above example demonstrates how Trial Sequential
Analysis can be used to determine the required sample
size for one or more additional RCTs to make a meta-
analysis more conclusive. This sample size would be
considered underpowered in comparison to a traditional
RCT sample size calculation. By using Trial Sequential
Analysis in such a way, future trials could be planned
using significantly fewer resources and with less cost
than trials planned using traditional sample size
calculations.
In the worked example, data from the pilot trial
were used in the Trial Sequential Analysis to estimate
the required information size. Ignoring that the same
data is being used twice (for the estimation and for
the meta-analysis) could mean that the estimate gen-
erated is not sufficiently conservative. Thus, we
present a modification which attempts to overcome
this issue. This approach increases the difference be-
tween required information size minus the accrued
information by the sample size of the trial used in
the estimation.
It is important to note that in the example, the meta-
analysis of the existing two MiQuit trials quantified het-
erogeneity as 0%, indicating no heterogeneity. However,
it is unlikely that this will be the case for meta-analyses
of other interventions aimed at changing addictive be-
haviours [33, 34]; therefore, trial sequential analysis
methods have been developed to account for this [22].
In Trial Sequential Analysis, estimated information size
and monitoring boundaries, vary with the level of het-
erogeneity in the meta-analysis, the greater the level of
heterogeneity, the larger the sample size and the wider
the monitoring boundaries needed to reach firm conclu-
sions about the effectiveness of the intervention. This is
because the required information size is calculated rela-
tive to the measure of heterogeneity, the fraction of the
accrued information size and the point estimate [18].
Sometimes trial design is adapted once a study has
begun; for example, one or more intervention arms may
be dropped and the sample size re-calculated. The
method demonstrated in this manuscript is different as
it involves using aggregated data in trial planning prior
to a study commencing; however, the statistical tech-
niques are analogous to those used in interim trial
analysis.
In the examples presented, odds ratios were also used
instead of relative risk, as the feasibility study was pow-
ered using an odds ratio from a meta-analysis investigat-
ing mobile phone interventions for smoking cessation in
the general population [7]. Moreover, the quit rates are
relatively low, so there is very little difference between
the odds ratio and relative risk. In other trial sequential
analyses, it may be advisable to use relative risks instead
of odds ratios, to avoid overestimates. Additionally, it
may be inappropriate to use the odds ratio used to
power the feasibility trial to estimate sample sizes for fu-
ture MiQuit trials since data now exists from the feasi-
bility and pilot trials. In our example, the stipulated
intervention effect was derived from the pilot trial (‘in-
ternal data’), and it may be argued that such adaptive
data should not be used in meta-analysis [35].
Kulinskaya and Wood argued that in an underpowered
meta-analysis, not only is it necessary to assess the gap
from the accrued information size to the required infor-
mation size (i.e. the number of additional participants
you need to randomise), but also the number of trials
that should be conducted to randomise this number of
participants [36]. Using multiple trials to reach the re-
quired information size may be beneficial in meta-
analyses where heterogeneity occurs [36]. Smaller trials
have more imprecise estimates of intervention effects;
hence heterogeneity is reduced in the meta-analysis of
such trials. However, setting up more than one trial can
be more expensive and may not be realistic in practice.
Recently, the Cochrane Collaboration evaluated and
updated their guidance on using sequential approaches
in meta-analysis in their reviews [5, 10, 37]. The
Cochrane Handbook authors concluded that sequential
methods should not be used in primary analyses or to
draw conclusions, but could be used as secondary ana-
lyses in reviews if they are prospectively planned and the
assumptions underlying the design are clearly justified
[5, 10]. In their guidance, the evidence synthesis group
state that authors’ interpretations of evidence should be
based on estimated magnitude of effect of an interven-
tion and its uncertainty rather than drawing binary con-
clusions, and decisions should not be influenced by
plans for future updates of meta-analyses [10]. These
criticisms of sequential approaches in meta-analyses
apply to the traditional use of Trial Sequential Analysis,
(See figure on previous page.)
Fig. 2 I. Trial Sequential Analysis output of the MiQuit feasibility trial with the pilot trial removed, using 90% power, 5% significance, to detect a
3.4% absolute difference. Diversity = 0%. Point A on the z-curve represents the feasibility trial. Monitoring boundaries in Fig. 1 use the Lan-DeMets
O’Brien-Fleming alpha-spending approach. II. Point C represents a theoretical trial with a sample size of 630 women, where an absolute
difference of 3.17% was observed, in favour of the MiQuit group, between the experimental versus the control group. Diversity = 0%. III. Point D
represents a theoretical trial with a sample size of 630 women, with an absolute difference of − 0.63% in favour of the control
group. Diversity = 30%
Claire et al. BMC Medical Research Methodology          (2020) 20:284 Page 8 of 10
whereas our paper demonstrates an alternative use of
the method.
Another reason given by The Cochrane Handbook au-
thors against using sequential methods as a primary ana-
lysis in reviews, is the argument that a meta-analyst does
not have any control over designing trials that are eli-
gible for meta-analysis [10]. It would therefore be impos-
sible to construct a set of stopping rules [10]. In our
example, the opposite is the case. Both the feasibility
and pilot trials were conducted by the same group of in-
vestigators, and any future trials would have a consider-
ation for the desired properties of a stopping rule.
Finally, The Cochrane Handbook authors also high-
light that there are methodological limitations to se-
quential methods when heterogeneity is present [10]. In
the example described in this paper, heterogeneity was
not detected, possibly due to the lack of sufficient power
to detect a moderate level. However, we do discuss how
the presence of heterogeneity can be overcome in Trial
Sequential Analysis by performing a sensitivity analysis.
Conclusions
In conclusion, Trial Sequential Analysis is a freely avail-
able software that can utilise data from feasibility and
pilot trials as well as other trials, in order to estimate a
sample size for one or more future RCTs, to provide an
adequately powered conclusion regarding an interven-
tion’s benefits and harms. This simple use of expensively
collected trial data could be usefully exploited by re-
searchers evaluating other interventions.
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